Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP40 protects podocytes by deubiquitylating integrin β1.

Biochemical and biophysical research communications·2026
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

Science translational medicine·2026
Same author

Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies.

Antibody therapeutics·2026
Same author

RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy.

Antibody therapeutics·2026

Related Experiment Video

Updated: Jun 26, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic

Ralph F Alderson1, Robert J Kreitman, Tianling Chen

  • 1Cambridge Antibody Technology, Inc., Palo Alto, California, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 4, 2009
PubMed
Summary

CAT-8015, a novel CD22-targeting immunotoxin, demonstrates significantly enhanced efficacy in preclinical studies compared to its predecessor, CAT-3888. This improved immunotoxin shows potent anti-tumor activity and comparable toxicity profiles.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Experiment Videos

Last Updated: Jun 26, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Recombinant immunotoxins are engineered proteins targeting cancer cells.
  • CD22 is a target antigen expressed on B-cell malignancies.
  • CAT-3888 is a parental immunotoxin with known anti-cancer activity.

Purpose of the Study:

  • To evaluate the in vitro and in vivo efficacy of CAT-8015, a second-generation anti-CD22 immunotoxin.
  • To compare the performance of CAT-8015 against its parental compound, CAT-3888.

Main Methods:

  • In vitro cytotoxicity assays using B-cell tumor lines.
  • In vivo efficacy studies in a xenograft tumor model.
  • Pharmacokinetic and toxicologic assessments in animal models (mice, rats, monkeys).

Main Results:

  • CAT-8015 exhibited potent in vitro activity with IC50 values ranging from 0.3 to 8.6 ng/mL.
  • In vivo studies showed significant tumor reduction and complete remission in some cases with CAT-8015 treatment.
  • Pharmacokinetic studies revealed varying half-lives and volumes of distribution across species.
  • Toxicologic studies indicated comparable safety profiles between CAT-8015 and CAT-3888.

Conclusions:

  • CAT-8015 represents a significant advancement in CD22-targeting immunotoxins.
  • Preclinical data support the enhanced efficacy of CAT-8015 over CAT-3888.
  • CAT-8015 warrants further investigation for potential therapeutic applications in B-cell malignancies.